The US Food and Drug Administration (USFDA) has issued a warning letter dated July 10, 2026, to a clinical investigator associated with a bioequivalence study conducted at Alembic Pharmaceuticals' Vadodara bioequivalence facility in Gujarat, relating to informed consent form (ICF) procedures used during the study.
Alembic disclosed that the observations pertain to documentation and process issues with the ICF, not to data integrity, and affirmed that the letter does not restrict operations at the bioequivalence facility or impose material financial impact at this stage.
Investors reacted with concern, and Alembic's shares fell about 2% as the episode raised scrutiny over US regulatory compliance and potential delays in Abbreviated New Drug Application (ANDA) reviews, though the company maintains that its data reliability and core manufacturing operations remain unaffected.
Sources:
FDA Issues Warning Letter to Alembic Pharma's Clinical ...
ЁЭРГЁЭРл.ЁЭРПЁЭРЪЁЭРлЁЭРв ЁЭРТ's Post
Alembic Pharma рдХो USFDA рд╕े рдЪेрддाрд╡рдиी рдкрдд्рд░: Vadodara рд╕ुрд╡िрдзा рдкрд░ ...
Alembic Pharma shares slide 2% after USFDA warning letter ...
USFDA Issues Warning Letter to Alembic Pharmaceuticals
Alembic Pharma Falls 2% on USFDA Warning Letter
Alembic Pharma Reports USFDA Warning Letter To Investigator With 0 Impact On Data Reliability